Alhamdulillah. Great news! The paper of my PhD student Muhammad Shah has been accepted in the highly prestigious European Journal of Medicinal Chemistry, which has an impact factor of 7.088. This journal is ranked in the top quartile (Q1) and falls under the W-category, emphasizing the significance of our research. We have identified for the first time thiazolidinedione-based potential multitarget antidiabetic therapeutic drug candidates having strong binding affinity towards DPP-4, PTP-1B, α-Amylase, and α-Glucosidase. The work was done by Muhammad Shah during his MS / M. Phil research.
I would like to express my heartfelt appreciation to my exceptional MS student (now in PhD), whose remarkable work played a crucial role in the success of this publication. I am also immensely grateful to my collaborators Dr. Abdul Sadiq and Dr. Muhammad Saeed Jan who contributed to this achievement.
Another paper on Multitarget Drug Design against Alzheimer’s disease has been published in Biomedicine & Pharmacotherapy (159 (2023) 114239). The title of the paper is: “Evaluation of pyrimidine/pyrrolidine-sertraline based hybrids as multitarget anti-Alzheimer agents: In-vitro, in-vivo, and computational studies”. The link is: https://www.sciencedirect.com/science/article/pii/S0753332223000276
Another article by my team has been accepted for publication in Bioorganic and Medicinal Chemistry Letters. Congratulations to hard-working students, Ridha Jadoon and Aamir Javed. The title of the paper is, Design, synthesis, in-vitro, in-vivo and ex-vivo pharmacology of thiazolidine-2,4-dione derivatives as selective and reversible monoamine oxidase-B inhibitors.